@article{ec134864ce6441b4954047d5f42d8cab,
title = "Oncolytic Measles Virotherapy and Opposition to Measles Vaccination",
abstract = "Recent measles epidemics in US and European cities where vaccination coverage has declined are providing a harsh reminder for the need to maintain protective levels of immunity across the entire population. Vaccine uptake rates have been declining in large part because of public misinformation regarding a possible association between measles vaccination and autism for which there is no scientific basis. The purpose of this article is to address a new misinformed antivaccination argument—that measles immunity is undesirable because measles virus is protective against cancer. Having worked for many years to develop engineered measles viruses as anticancer therapies, we have concluded (1) that measles is not protective against cancer and (2) that its potential utility as a cancer therapy will be enhanced, not diminished, by prior vaccination.",
author = "Russell, {Stephen J.} and Dusica Babovic-Vuksanovic and Alice Bexon and Roberto Cattaneo and David Dingli and Angela Dispenzieri and Deyle, {David R.} and Federspiel, {Mark J.} and Adele Fielding and Eva Galanis and Lacy, {Martha Q.} and Leibovich, {Bradley C.} and Liu, {Minetta C.} and Miguel Mu{\~n}oz-Al{\'i}a and Miest, {Tanner C.} and Molina, {Julian R.} and Sabine Mueller and Okuno, {Scott H.} and Nandakumar Packiriswamy and Tobias Peikert and Corey Raffel and {Van Rhee}, Frits and Guy Ungerechts and Young, {Paul R.} and Yumei Zhou and Peng, {Kah Whye}",
note = "Funding Information: Potential Competing Interests: Oncolytic measles technology has been licensed from Mayo Clinic to Vyriad. Drs Russell, Bexon, and Peng and Mayo Clinic have a financial interest in Vyriad. Dr Babovic-Vuksanovic is a consultant for Loeb & Loeb LLP. Dr Dispenzieri is a member of the advisory board for Janssen Pharmaceuticals, Inc, has received travel expenses from Pfizer Inc, and has received research funding from Celgene Corporation, Alnylam Pharmaceuticals, Takeda Pharmaceutical Company Limited, Pfizer, GlaxoSmithKline plc., and Prothena (all funds paid to her institution). Dr Galanis is a consultant for Tactical Therapeutics, Inc, has received grants from MedImmune (funds paid to her institution), and has received other compensation from Celegene Corporation and KIYATEC, Inc. Dr Liu has been a consultant for Celgene Corporation, Genentech, Inc, GRAIL, Inc, Ionis Pharmaceuticals, Inc, Merck & Co, Inc, Pfizer Inc, and Syndax (all funds paid to her institution) and has received funds to support the conduct of clinical trials from Eisai, Genentech, GRAIL, Inc, Janssen Pharmaceuticals, Merck, Novartis Pharmaceuticals Corporation, Seattle Genetics, and TESARO, Inc (all funds paid to her institution). Potential Competing Interests: Oncolytic measles technology has been licensed from Mayo Clinic to Vyriad. Drs Russell, Bexon, and Peng and Mayo Clinic have a financial interest in Vyriad. Dr Babovic-Vuksanovic is a consultant for Loeb & Loeb LLP. Dr Dispenzieri is a member of the advisory board for Janssen Pharmaceuticals, Inc, has received travel expenses from Pfizer Inc, and has received research funding from Celgene Corporation, Alnylam Pharmaceuticals, Takeda Pharmaceutical Company Limited, Pfizer, GlaxoSmithKline plc., and Prothena (all funds paid to her institution). Dr Galanis is a consultant for Tactical Therapeutics, Inc, has received grants from MedImmune (funds paid to her institution), and has received other compensation from Celegene Corporation and KIYATEC, Inc. Dr Liu has been a consultant for Celgene Corporation, Genentech, Inc, GRAIL, Inc, Ionis Pharmaceuticals, Inc, Merck & Co, Inc, Pfizer Inc, and Syndax (all funds paid to her institution) and has received funds to support the conduct of clinical trials from Eisai, Genentech, GRAIL, Inc, Janssen Pharmaceuticals, Merck, Novartis Pharmaceuticals Corporation, Seattle Genetics, and TESARO, Inc (all funds paid to her institution). Publisher Copyright: {\textcopyright} 2019 Mayo Foundation for Medical Education and Research",
year = "2019",
month = sep,
doi = "10.1016/j.mayocp.2019.05.006",
language = "English (US)",
volume = "94",
pages = "1834--1839",
journal = "Mayo Clinic proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "9",
}